Numinus Wellness Inc (CVE: NUMI) (OTCMKTS: LKYSF) is making a powerful run up the charts in recent months since the Company reported it has begun cultivating psilocybin mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility. “We are thrilled to start growing mushrooms at our laboratory under our Health Canada license,” says Michael Tan, Chief Operating Officer. “We envision a day when the option of natural, plant-based psilocybin is available for use in therapies at Numinus Clinics and by others, and this is a tangible step towards that goal.”
Several clinical trials are underway in the United States and worldwide to investigate the therapeutic effects of psilocybin, and there is new hope for treating such debilitating disorders as depression, anxiety, post-traumatic stress disorder, anorexia, obsessive-compulsive disorder, and addiction. With an estimated psilocybin market size of $6.9 billion by 2027, Companies such as CMPS, FTRP, LKYSF, and MMEDF are seeing big runs.
Numinus Wellness Inc (CVE: NUMI) (OTCMKTS: LKYSF) is a Vancouver-based health care company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies. Numinus’ ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten legal, for-profit psychedelic-assisted therapy models and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies.
Numinus Bioscience includes a 7,000 square foot research and testing laboratory as well as numerous Health Canada licenses (through its wholly-owned subsidiary Salvation Botanicals) including a cannabis testing license used for sustainable B2B revenue to support the company’s psychedelic efforts. The company holds a Dealer’s License which allows it to import, export, possess, and test MDMA, psilocybin, psilocin, DMT and mescaline as well as a license to produce and extract psilocybin from mushrooms. These licenses allow Numinus to support the growing number of studies on the potential benefits of psychedelic-assisted psychotherapies through research projects, product development, and the supply and distribution of these substances. Numinus R&D is embarking on implementation science and leveraging established relationships for partnerships to host studies, develop medical and therapeutic protocols, and influence regulatory approval. Numinus Health is dedicated to delivering therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health — centred around safe, evidence-based accessible psychedelic-assisted psychotherapy.
Numinus Wellness took of in September after the Company announced it has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility. Psilocybin-assisted psychotherapy is currently being studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders. Under its Health Canada license for the production and extraction of psilocybin from mushrooms, Numinus intends to cultivate and harvest the mushrooms.
Numinus’ vertically integrated ecosystem positions the Company to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated. From product development and supply, to analytics and testing, to clinical protocol development and implementation science in partnership with leading research organizations, the ecosystem approach allows Numinus to ensure quality control and best-in-class delivery with steady revenue streams to support its developments.
To Find out the inside Scoop on Numinus Wellness Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Numinus continues to make progress in all units of its ecosystem. Other recent developments include: Numinus Health — Upgrades have commenced on the existing wellness clinic for compliance to the Multidisciplinary Association of Psychedelics Studies (MAPS) specifications for psychedelic-assisted psychotherapies, to ready the clinic for delivery of therapies and to provide a blueprint for the expansion of Numinus clinics in a range of jurisdictions in the future. In addition, the Company is fast-tracking plans for virtual delivery of transformative health solutions to counter COVID-related risks.
Numinus R&D — Refinements are being implemented in the Company’s clinical protocols to support MDMA and psilocybin research, and partnership discussions with leading research organizations are progressing, with the goal of making these substances accessible in a research context before they are widely available on the market.
Numinus Bioscience — The laboratory is preparing to add additional revenue streams as a contract analytical and research lab for psychedelic substances including MDMA, psilocybin, psilocin, DMT, and mescaline under its Health Canada Controlled Drugs and Substances licence.
Numinus CEO and founder Payton Nyquvest stated:”Numinus is setting the stage – and establishing its leadership position – for a future state where psychedelic-assisted psychotherapies are approved for clinical use outside of research. We are progressing on our mission right now by creating the infrastructure and advancing evidence-based research to support routine clinical use in the health care system. We have the infrastructure, licenses, resources, and expertise to help hasten evidence-based accessibility to these treatments so we can, ultimately, help people heal and be well.”
— ScubaTrades (@ScubaTrades) December 11, 2020
For More on Numinus Wellness Subscribe Right Now!
Numinus Wellness is making a powerful run up the charts in recent months since the Company reported it has begun cultivating psilocybin mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility. The Company’s laboratory is busy preparing to add additional revenue streams as a contract analytical and research lab for psychedelic substances including MDMA, psilocybin, psilocin, DMT, and mescaline under its Health Canada Controlled Drugs and Substances license. The psychedelic market recently saw a large move towards legitimacy in the eye of corporate America with the IPO of Compass Pathways. The psychedelic marketplace is forecasted to be nearly a $6.9 billion business by 2027 and Numinus Wellness is an early mover and shaker in the space. We will be updating on Numinus Wellness on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Numinus Wellness .
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in Numinus Wellness either long or short and we have not been compensated for this article.